• Sirnaomics completed first-patient dosing in a Phase II trial of STP705 for medical aesthetic use.
• No results have been presented yet; the study is designed to generate future efficacy and safety readouts.
• Trial focus is whether locally administered STP705 can reduce targeted subcutaneous fat with acceptable tolerability.
• Data are intended to support global development of STP705 as a minimally invasive alternative to existing fat-reduction approaches.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sirnaomics Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260730-12261921), on July 30, 2026, and is solely responsible for the information contained therein.